Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 20/20 | 0.63 |
| ▸ | INSR | P06213 | 10/20 | 0.63 |
| ▸ | NPM1 | P06748 | 7/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12246332 | 0.93 | ALK (0.58) | ALKINSRNPM1KCNH2CYP3A4 | |
| SCHEMBL12245784 | 0.93 | ALK (0.62) | ALKINSRNPM1KCNH2CYP3A4 | |
| SCHEMBL12245797 | 0.92 | ALK (0.62) | ALKINSRNPM1KCNH2CYP3A4 | |
| SCHEMBL12246335 | 0.91 | ALK (0.61) | ALKINSRNPM1KCNH2CYP3A4 | |
| SCHEMBL12247488 | 0.91 | ALK (0.62) | ALKINSRNPM1KCNH2CYP3A4 | |
| SCHEMBL12246334 | 0.90 | ALK (0.63) | ALKINSRNPM1KCNH2CYP3A4 | |
| SCHEMBL12247489 | 0.90 | ALK (0.64) | ALKINSRNPM1KCNH2CYP3A4 | |
| SCHEMBL12246328 | 0.88 | ALK (0.63) | ALKINSRNPM1KCNH2CYP3A4 | |
| SCHEMBL12388945 | 0.87 | ALK (0.75) | ALKINSRNPM1KCNH2CYP3A4 | |
| SCHEMBL1546097 | 0.86 | ALK (0.85) | ALKINSRNPM1KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372858-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2013-02-12 | — | — | US | disclosed |
| US-20110190259-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190259-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | ALK 23/4885INSR 67/4885NPM1 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.